Additional file 1 of LncRNA-BC069792 suppresses tumor progression by targeting KCNQ4 in breast cancer

Additional file 1: Supplementary Fig. 1. a In breast cancer cell line and non-tumor cell line MCF-10A, the expression of BC069792 was the highest in non-tumor cell line MCF-10A, while in breast cancer cell line, the expression of BC069792 in MDA-MB-231 and MDA-MB-468 cell lines was the lowest. b CCK-8 experiments showed that si-BC069792 can promote the proliferation of MDA-MB-231 cells (*P=0.43) and MDA-MB-468 (*P=0.026) cells. c The results of EdU experiments showed that si-BC069792 promoted the proliferation ability of breast MDA-MB-231 (*P=0.042) and MDA-MB-468 (*P=0.050) cancer cells. d Compared with the control group, the si-BC069792 knockdown group can effectively promote the migration (P=0.044) and invasion ability (P=0.002) of MDA-MB-231 cells, while the si-BC069792 knockdown group can effectively promote the migration (P=0.002) and invasion (**P=0.005) of MDA-MB-468 cells, and the number of cells passing through the underfloor membrane of the chamber is significantly increased. *P< 0.05, **P< 0.01, ***P< 0.001. Supplementary Fig. 2. Wound healing experiment confirmed that BC069792 can effectively inhibit the migration ability of breast cancer cells. Supplementary Fig. 3. Gene differential expression results after breast cancer cells overexpressed BC069792 a The results of principal component analysis showed that the consistency within the two sample groups was good and had difference. b The results of gene difference analysis showed that the BC069792 overexpression group could cause differential expression of 1209 downstream genes. c The differential expression pathway shown in the figure related to the transduction function of synaptic transmission signal. Supplementary Fig. 4. The exprssion of KCNQ4 protein in the knockdown BC069792 group was significantly reduced (*p=0.014).

附加文件1：补充图1。a. 在乳腺癌细胞系与非肿瘤细胞系MCF-10A中，BC069792在非肿瘤细胞系MCF-10A内的表达水平最高；而在乳腺癌细胞系中，MDA-MB-231与MDA-MB-468细胞系内BC069792的表达水平最低。b. CCK-8实验结果显示，靶向BC069792的小干扰RNA（si-BC069792）可促进MDA-MB-231细胞（*P=0.43）与MDA-MB-468细胞（*P=0.026）的增殖。c. EdU实验结果显示，si-BC069792可增强乳腺癌MDA-MB-231细胞（*P=0.042）与MDA-MB-468细胞（*P=0.050）的增殖能力。d. 与对照组相比，si-BC069792敲低组可有效增强MDA-MB-231细胞的迁移能力（P=0.044）与侵袭能力（P=0.002）；同时，si-BC069792敲低组亦可有效促进MDA-MB-468细胞的迁移能力（P=0.002）与侵袭能力（**P=0.005），且穿过Transwell小室基底膜的细胞数量显著增加。*P<0.05，**P<0.01，***P<0.001。
补充图2：划痕实验证实BC069792可有效抑制乳腺癌细胞的迁移能力。
补充图3：乳腺癌细胞过表达BC069792后的基因差异表达结果。a. 主成分分析结果显示，两组样本组内一致性良好且组间存在显著差异。b. 基因差异分析结果显示，BC069792过表达组可导致1209个下游基因出现差异表达。c. 图中展示的差异表达通路与突触传递信号转导功能相关。
补充图4：敲低BC069792组中KCNQ4蛋白的表达水平显著降低（*P=0.014）。